Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q1 FY26 results · Apr–Jun 2025
Panacea Biotec reported revenue from operations of ₹166.70 crore (up 44.1% from Q1 FY25) and net profit of ₹3.96 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 166.70 | 115.72 | +44.1% | 132.53 | +25.8% |
| Other income | 5.67 | 3.80 | +49.2% | 8.59 | −34.0% |
| Total income | 172.37 | 119.52 | +44.2% | 141.12 | +22.1% |
| Profit before tax | 6.56 | (17.05) | Turned profit | (0.04) | Turned profit |
| Net profit for the period | 3.96 | (15.88) | Turned profit | (1.99) | Turned profit |
| Attributable to shareholders of the company | 4.05 | (15.80) | Turned profit | (1.89) | Turned profit |
| EPS, basic (₹) | 0.66 | (2.59) | Turned profit | (0.31) | Turned profit |
| Net margin (%) | 2.4 | -13.7 | -1.5 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.25 | 56.88 | +97.3% | 67.90 | +65.3% |
| Other income | 4.95 | 3.80 | +30.3% | 6.09 | −18.7% |
| Total income | 117.20 | 60.68 | +93.1% | 73.99 | +58.4% |
| Profit before tax | (8.84) | (14.98) | Loss narrowed | (22.03) | Loss narrowed |
| Net profit for the period | (6.70) | (13.78) | Loss narrowed | (12.39) | Loss narrowed |
| EPS, basic (₹) | (1.09) | (2.25) | Loss narrowed | (2.02) | Loss narrowed |
| Net margin (%) | -6.0 | -24.2 | -18.2 |
Consolidated
- Filed with BSE
- 14 Aug 2025, 18:10 IST
- Board meeting
- 14 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2025, 18:10 IST
- Board meeting
- 14 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE